• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Singular Genomics Systems Inc. (Amendment)

    2/14/23 7:43:52 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OMIC alert in real time by email
    SC 13G/A 1 d444877dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Singular Genomics Systems, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    82933R100

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☑ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 82933R100    SCHEDULE 13G    Page 2 of 9 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Revelation Alpine, LLC

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☑

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      1,184,497

       6.   

      SHARED VOTING POWER

     

      0

       7.   

      SOLE DISPOSITIVE POWER

     

      1,184,497

       8.   

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,184,497

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      1.7% (1)

    12.  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. 82933R100    SCHEDULE 13G    Page 3 of 9 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Revelation Alpine GP, LLC

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☑

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      1,184,497

       6.   

      SHARED VOTING POWER

     

      0

       7.   

      SOLE DISPOSITIVE POWER

     

      1,184,497

       8.   

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,184,497

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      1.7% (1)

    12.  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. 82933R100    SCHEDULE 13G    Page 4 of 9 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Revelation Healthcare Fund II, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☑

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      231,349

       6.   

      SHARED VOTING POWER

     

      0

       7.   

      SOLE DISPOSITIVE POWER

     

      231,349

       8.   

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      231,349

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      0.3% (1)

    12.  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. 82933R100    SCHEDULE 13G    Page 5 of 9 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Revelation Healthcare Fund II GP, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☑

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      231,349

       6.   

      SHARED VOTING POWER

     

      0

       7.   

      SOLE DISPOSITIVE POWER

     

      231,349

       8.   

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      231,349

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      0.3% (1)

    12.  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. 82933R100    SCHEDULE 13G    Page 6 of 9 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Revelation Healthcare Fund II GP, LLC

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☑

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      231,349

       6.   

      SHARED VOTING POWER

     

      0

       7.   

      SOLE DISPOSITIVE POWER

     

      231,349

       8.   

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      231,349

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      0.3% (1)

    12.  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. 82933R100    SCHEDULE 13G    Page 7 of 9 Pages

     

    Item 1.

            

    Issuer

      

    (a)

         

    Name of Issuer:

            

    Singular Genomics Systems, Inc. (the “Issuer”)

      

    (b)

         

    Address of Issuer’s Principal Executive Offices:

            

    3010 Science Park Road

    San Diego, CA 92121

    Item 2.

            

    Filing Person

      

    (a) – (c)

         

    Name of Persons Filing; Address; Citizenship:

            

    (i) Revelation Alpine, LLC, a Delaware limited liability company (“Alpine”).

     

    (ii)  Revelation Alpine GP, LLC, a Delaware limited liability company (“Alpine GP”).

     

    (iii)  Revelation Healthcare Fund II, L.P., a Delaware limited partnership (“Healthcare Fund II”).

     

    (iv) Revelation Healthcare Fund II GP, L.P., a Delaware limited partnership (“Healthcare Fund II GP LP”).

     

    (v)   Revelation Healthcare Fund II GP, LLC, a Delaware limited liability company (“Healthcare Fund II GP LLC”).

     

    The address of the principal business office of each of the Reporting Persons is 300 Turney Street, Sausalito, CA 94965.

      

    (d)

         

    Title of Class of Securities:

            

    Common Stock, par value $0.0001 per share

      

    (e)

         

    CUSIP Number:

     

    82933R100

    Item 3.

      

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

      

    (a)

      

    ☐

       Broker or dealer registered under Section 15 of the Act;
      

    (b)

      

    ☐

       Bank as defined in Section 3(a)(6) of the Act;
      

    (c)

      

    ☐

       Insurance company as defined in Section 3(a)(19) of the Act;
      

    (d)

      

    ☐

       Investment company registered under Section 8 of the Investment Company Act of 1940;
      

    (e)

      

    ☐

       An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      

    (f)

      

    ☐

       An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      

    (g)

      

    ☐

       A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      

    (h)

      

    ☐

       A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      

    (i)

      

    ☐

       A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      

    (j)

      

    ☐

       A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      

    (k)

      

    ☐

       Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
          If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    CUSIP No. 82933R100    SCHEDULE 13G    Page 8 of 9 Pages

     

    Item 4.    Ownership.
         (a) and (b)    Amount beneficially owned:
              (i)    Alpine directly owns 1,184,497 shares of Common Stock, which represents approximately 1.7% of the
    outstanding shares of Common Stock. Alpine GP, as general partner of Alpine, may be deemed to
    beneficially own the shares of Common Stock held directly by Alpine.
              (ii)    Healthcare Fund II directly owns 231,349 shares of Common Stock, which represents approximately
    0.3% of the outstanding shares of Common Stock. Healthcare Fund II GP LP, as general partner of
    Healthcare Fund II, and Healthcare Fund II GP LLC, as general partner of Healthcare Fund II GP LP,
    may each be deemed to beneficially own the shares of Common Stock held directly by Healthcare Fund
    II.
                             (c)   Number of shares as to which such person has:
                              
                           
         Number of Shares of Common Stock  

    Reporting Person

       (i)      (ii)      (iii)      (iv)  

    Alpine

         1,184,497        0        1,184,497        0  
    Alpine GP      1,184,497        0        1,184,497        0  
    Healthcare Fund II      231,349        0        231,349        0  
    Healthcare Fund II GP LP      231,349        0        231,349        0  
    Healthcare Fund II GP LLC      231,349        0        231,349        0  
         (i) Sole power to vote or direct the vote
    (ii)  Shared power to vote or to direct the vote
    (iii)  Sole power to dispose or to direct the disposition of
    (iv) Shared power to dispose or to direct the disposition of
         The percentage of class was calculated based on 71,396,110 shares of Common Stock outstanding as of October 31, 2022,
    as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on
    November 7, 2022.
    Item 5.   

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: ☑

    Item 6.   

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

    Item 7.   

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

    Item 8.   

    Identification and Classification of Members of the Group.

     

    Not applicable.

    Item 9.   

    Notice of Dissolution of Group.

     

    Not applicable.

    Item 10.   

    Certification.

     

    Not applicable.


    CUSIP No. 82933R100    SCHEDULE 13G    Page 9 of 9 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2023

     

    REVELATION ALPINE, LLC
    By: Revelation Alpine GP, LLC
    Its: General Partner
    By:   /s/ Michael Boggs
    Name:   Michael Boggs
    Title:   Managing Member
    REVELATION ALPINE GP, LLC
    By:   /s/ Michael Boggs
    Name:   Michael Boggs
    Title:   Managing Member
    REVELATION HEALTHCARE FUND II, L.P.
    By: Revelation Healthcare Fund II GP, L.P.
    Its: General Partner
    By: Revelation Healthcare Fund II GP, LLC
    Its: General Partner
    By:   /s/ Michael Boggs
    Name:   Michael Boggs
    Title:   Managing Member
    REVELATION HEALTHCARE FUND II GP, L.P.
    By: Revelation Healthcare Fund II GP, LLC
    Its: General Partner
    By:   /s/ Michael Boggs
    Name:   Michael Boggs
    Title:   Managing Member
    REVELATION HEALTHCARE FUND II, LLC
    By:   /s/ Michael Boggs
    Name:   Michael Boggs
    Title:   Managing Member
    Get the next $OMIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMIC

    DatePrice TargetRatingAnalyst
    8/17/2022$10.00 → $4.50Buy → Neutral
    UBS
    8/10/2022$3.50Buy → Neutral
    Goldman
    8/10/2022$3.00Buy → Underperform
    BofA Securities
    1/7/2022$21.00Neutral → Buy
    BofA Securities
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $OMIC
    SEC Filings

    View All

    Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant

    8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)

    2/27/25 1:42:39 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.

    SCHEDULE 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

    2/25/25 9:18:06 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form EFFECT filed by Singular Genomics Systems Inc.

    EFFECT - Singular Genomics Systems, Inc. (0001850906) (Filer)

    2/24/25 12:15:05 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    2/27/25 8:54:47 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    2/25/25 8:12:58 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    2/25/25 8:11:40 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT

    SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X™ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida. G4X Early Access Program Ongoing and Broader Availability on Track The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform's real-world potential. "As the first early access site, we've had the chance to

    2/24/25 8:00:00 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Announces Closing of Acquisition by Deerfield Management

    SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.    On December 23, 2024, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common stock not currently owned by Deerfield for $20.00 per share in cash. Following the satisfaction of customary conditions, including a vote of the holders of Singular Genomics' common stock to approv

    2/21/25 9:56:26 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share

    SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC) ("Singular Genomics" or the "Company"), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has entered into a definitive merger agreement whereby an affiliate of Deerfield Management Company, L.P. will acquire Singular Genomics in an all-cash transaction for $20.00 per share. The $20.00 per share represents 254% premium to the last closing share price for Singular's common stock prior to the September 12, 2024 public disclosure of Deerfield's initial acquisition proposal. The Singular Genomic

    12/23/24 8:30:00 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tang Kevin bought $1,806,220 worth of shares (122,416 units at $14.75) (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    9/18/24 4:31:08 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Spaventa Andrew bought $49,612 worth of shares (118,468 units at $0.42) (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    11/20/23 4:31:38 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Glezer Eli N. bought $85,640 worth of shares (200,000 units at $0.43), increasing direct ownership by 5% to 4,570,000 units (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    11/20/23 4:30:55 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Financials

    Live finance-specific insights

    View All

    Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results

    SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2024. "In the third quarter, we made significant progress in the development of the G4X spatial sequencer," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "We are encouraged by the interest in the G4X and validation received through the expansion of our Spatial Technology Access Services project funnel, which reinfo

    11/12/24 4:05:00 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

    SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2024. "It was another busy and productive quarter for our team as we progressed development of the G4X Spatial Sequencer while supporting our G4 customers," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "The early interest in our Spatial Technology Access Services is an encouraging sign that the unique capabilities and

    8/13/24 4:05:00 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024

    SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 66

    7/30/24 5:05:42 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Singular Genomics Systems downgraded by UBS with a new price target

    UBS downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $4.50 from $10.00 previously

    8/17/22 9:15:00 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Systems downgraded by Goldman with a new price target

    Goldman downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $3.50

    8/10/22 6:31:06 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Systems downgraded by BofA Securities with a new price target

    BofA Securities downgraded Singular Genomics Systems from Buy to Underperform and set a new price target of $3.00

    8/10/22 6:30:40 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Leadership Updates

    Live Leadership Updates

    View All

    Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

    SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company's Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE:LH) and brings more than 30 years of experience with molecular genetics, DNA testing, biotechnology, and molecular oncology. "Marcia's deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to w

    8/8/23 4:05:00 PM ET
    $LH
    $OMIC
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Appoints Sam Ropp, Ph.D., as Chief Commercial Officer

    SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer. In this role, Dr. Ropp will oversee the company's commercial function, including commercialization of the G4 Sequencing Platform. He will report to Drew Spaventa, Chief Executive Officer and Founder of Singular Genomics. The company also announced the appointment of Jeff Bullard as Head of Sales for North America. "As an accomplished life science leader, Sam brings the deep knowledge and experi

    8/2/22 7:30:00 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors

    LA JOLLA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company's Board of Directors. Dr. Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment. "We are thrilled to have Elaine join the Board of Directors. She brings the rare combination of world-class scientific, indust

    1/6/22 4:05:00 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

    SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

    11/22/24 7:55:51 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13D filed by Singular Genomics Systems Inc.

    SC 13D - Singular Genomics Systems, Inc. (0001850906) (Subject)

    11/5/24 7:29:21 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

    SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

    11/1/24 7:54:29 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials